



Q4 2021 法人說明會

IR Contact/Spokesperson
Mandy Huang
mandy.huang@mbi.com.tw


SAFE HARBOR NOTICE

TCL's statements of its current expectations are forwardlooking statements subject to significant risks and uncertainties and actual results may differ materially from those contained in the forward-looking statements.


Except as required by law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

膠原蛋白及玻尿酸生技醫療公司

股票代號 1783
員工數 150 人
2021 年營收 NTD 5.12 億元




現有產品已於全球各國銷售




專注於膠原蛋白及玻尿酸生技領域

營收分佈 依產品
Sales Breakdown - by Product


● HYALURONIC ACID RELATED ● COLLAGEN RELATED ● OTHER



FY 2019



FY 2020




FY 2021


營收分佈 依區域

Sales Breakdown – by Region


● TAIWAN ● US ● EU ● CHINA ● ASIA ● OTHER



FY 2019



FY 2020



FY 2021

投入研發 產品全面擴大應用


延伸應用範圍
並加入自有品牌保健品

醫材CDMO


高階萃取
及
合成技術



自有品牌原料



MAXICOLLAGEN
ABSOLUTELY SUPREME
膠原蛋白



MAXIHA
HYALURONIC ACID
玻尿酸



大江集團資源整合 擴大成長引擎



CN, US
EU(FR, NL, DE, IT, ES, RU)
TW, JP, ID, TH



直銷/微商



電商



CPG品牌



直播



通路商

保健品與醫療通路綜效



2021 財務總覽

Financial Review



2021 第四季財務報表摘要

Q4 2021 Consolidated Financial Report

(新台幣百萬)

	Q4 2021 Amount	%	Q3 2021 Amount	%	QoQ %	Q4 2020 Amount	%	YoY %
營業收入	141	100%	139	100%	1%	123	100%	15%
營業毛利	69	49%	69	50%	0%	62	47%	11%
營業費用	-53	-38%	-38	-27%	39%	-38	-36%	39%
- 推銷費用	-11	-8%	-10	-7%	10%	-9	-7%	22%
- 管理費用	-16	-11%	-11	-8%	45%	-12	-12%	33%
- 研發費用	-26	-18%	-14	-10%	86%	-17	-17%	53%
- 預期信用損失	0	0%	-3	-2%	-100%	0	0%	-
營業利潤	16	11%	31	22%	-48%	24	11%	-33%
營業外收入	1	1%	2	1%	-50%	1	3%	-
所得稅費用	-3	-2%	-2	-1%	50%	-5	-3%	-40%
稅後淨利	14	10%	31	22%	-55%	20	11%	-30%
淨利歸屬於母公司業主	14	10%	31	22%	-55%	12	10%	17%
基本每股盈餘	0.17		0.42			0.29		

2021 財務報表摘要

2021 Consolidated Financial Report

(新台幣百萬)

	2021 Amount	%	2020 Amount	%	YoY %
營業收入	512	100%	458	100%	12%
營業毛利	261	51%	214	47%	22%
營業費用	-171	-33%	-153	-33%	12%
- 推銷費用	-40	-8%	-34	-7%	18%
- 管理費用	-53	-10%	-50	-11%	6%
- 研發費用	-75	-15%	-69	-15%	9%
- 預期信用損失	-3	-1%	0	0%	-
營業利潤	90	18%	61	13%	48%
營業外收入	8	2%	15	3%	-47%
所得稅費用	-10	-2%	-13	-3%	-23%
稅後淨利	88	17%	63	14%	40%
淨利歸屬於母公司業主	88	17%	63	14%	40%
基本每股盈餘	1.21		0.91		

資產負債表摘要

Balance Sheet

(新台幣百萬)	Q4 2021 Amount	%	Q3 2021 Amount	%	Q2 2021 Amount	%
現金及約當現金	513	41%	446	36%	209	21%
應收帳款	110	9%	127	10%	116	11%
存貨	79	6%	92	7%	98	10%
不動產 廠房 及設備	456	36%	459	37%	461	45%
資產總計	1,265	100%	1,241	100%	1,016	100%
短期借款	-	0%	-	0%	-	0%
流動負債合計	116	9%	108	9%	104	10%
負債總計	123	10%	116	9%	113	11%
權益總計	1,142	90%	1,125	91%	903	89%

現金流量表摘要

Cash Flow Statement

(新台幣百萬)	Q4 2021 Amount	Q3 2021 Amount	Q4 2020 Amount
期初現金及約當現金	210	210	268
營業活動之淨現金流入(流出)	117	72	74
投資活動之淨現金流入(流出)	-3	-25	139
籌資活動之淨現金流入(流出)	189	189	-271
匯率影響數	0	0	0
期末現金及約當現金	513	446	210
自由現金流	102	61	63

自由現金流=營運現金淨流入-資本支出

重要財務資訊

Other Financial Info

	2016 Amount	%	2017 Amount	%	2018 Amount	%	2019 Amount	%	2020 Amount	%	2021 Amount	%
每股盈餘	-0.18		0.23		0.82		0.87		0.91		1.21	-
股息	-	-	0.1503	65.3%	0.6805	82.9%	0.78	89.6%	0.7307	80.3%	1	82.6%
- 現金	-	-	0.1503	65.3%	0.6805	82.9%	0.78	89.6%	0.7307	80.3%	0	-
- 股票	-	-	-	-	-	-	-	-	-	-	1	82.6%
實收股本 (百萬)	708		708		708		695		695		770	
股東權益報酬率	-1.57%		1.98%		6.77%		7.06%		7.35%		7.68%	
資產報酬率	-1.08%		1.43%		5.10%		5.18%		5.91%		7.89%	
現金及約當現金 (百萬)	97		182		185		268		210		513	
負債比率	28.8%		27.9%		25.8%		28.2%		10.1%		10.8%	
EBITDA利潤率	3.3%		10.9%		20.3%		24.1%		24.1%		25.6%	

穩健提升獲利能力

